{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:42:59Z","timestamp":1782351779169,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13760-024-02572-3","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T19:01:43Z","timestamp":1716231703000},"page":"1385-1391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up"],"prefix":"10.1007","volume":"124","author":[{"given":"Tugba","family":"Erdogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagri","family":"Cansu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belgin","family":"Kocer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedanur","family":"Akkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin","family":"Kokmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"2572_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/B978-0-444-52001-2.00010-8","volume":"122","author":"DS Goodin","year":"2014","unstructured":"Goodin DS (2014) The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 122:231\u2013266","journal-title":"Handb Clin Neurol"},{"key":"2572_CR2","unstructured":"Flynn JP, Gerriets V (2022) Ocrelizumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC"},{"issue":"4","key":"2572_CR3","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125(4):1678\u20131685","journal-title":"J Immunol"},{"issue":"8","key":"2572_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","volume":"35","author":"N Seery","year":"2021","unstructured":"Seery N, Sharmin S, Li V et al (2021) Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study. CNS Drugs 35(8):907\u2013918","journal-title":"CNS Drugs"},{"issue":"1","key":"2572_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy356","volume":"6","author":"MR Ciardi","year":"2018","unstructured":"Ciardi MR, Iannetta M, Zingaropoli MA et al (2018) Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis 6(1):ofy356","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"2572_CR6","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00415-022-11009-x","volume":"269","author":"AR Buonomo","year":"2022","unstructured":"Buonomo AR, Viceconte G, Calabrese M et al (2022) Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol 269(6):3301\u20133307","journal-title":"J Neurol"},{"key":"2572_CR7","unstructured":"Smoot K (2019) The impact of ocrelizumab on immunoglobulin levels and the risk of infection. In: Moreno C, Stuchiner T, Chen C, Cohan S (ed) ECTRIMS Online Library"},{"issue":"10","key":"2572_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761\u20131766","journal-title":"J Rheumatol"},{"issue":"2","key":"2572_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1352458517751861","volume":"24","author":"WM Carroll","year":"2018","unstructured":"Carroll WM (2018) 2017 McDonald MS diagnostic criteria: evidence-based revisions. Mult Scler 24(2):92\u201395","journal-title":"Mult Scler"},{"issue":"3","key":"2572_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234","journal-title":"N Engl J Med"},{"issue":"3","key":"2572_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220","journal-title":"N Engl J Med"},{"issue":"5","key":"2572_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","volume":"265","author":"EC Tallantyre","year":"2018","unstructured":"Tallantyre EC, Whittam DH, Jolles S et al (2018) Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol 265(5):1115\u20131122","journal-title":"J Neurol"},{"key":"2572_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.770124","volume":"8","author":"Y Chang","year":"2022","unstructured":"Chang Y, Jeong SW, Jang JY (2022) Hepatitis B virus reactivation associated with therapeutic interventions. Front Med (Lausanne) 8:770124","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"2572_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau G, Yu ML, Wong G et al (2021) APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 15(5):1031\u20131048","journal-title":"Hepatol Int"},{"issue":"2","key":"2572_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3350\/cmh.2016.0024","volume":"22","author":"V Pattullo","year":"2016","unstructured":"Pattullo V (2016) Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 22(2):219\u2013237","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"2572_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5152\/tjg.2018.18263","volume":"29","author":"B Aygen","year":"2018","unstructured":"Aygen B, Demir AM, G\u00fcm\u00fc\u015f M et al (2018) Immunosuppressive therapy and the risk of hepatitis B reactivation: consensus report. Turk J Gastroenterol 29(3):259\u2013269","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"2572_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT (2015) American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(1):221\u201344.e3","journal-title":"Gastroenterology"},{"key":"2572_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104941","volume":"79","author":"R Alroughani","year":"2023","unstructured":"Alroughani R, AlMojel M, Al-Hashel J, Ahmed SF (2023) Real world study of ocrelizumab in multiple sclerosis: Kuwait experience. Mult Scler Relat Disord 79:104941","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2572_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2020-000108","volume":"3","author":"K Smoot","year":"2021","unstructured":"Smoot K, Chen C, Stuchiner T, Lucas L, Grote L, Cohan S (2021) Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study. BMJ Neurol Open 3(2):e000108","journal-title":"BMJ Neurol Open"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02572-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:46:17Z","timestamp":1721789177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02572-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02572-3","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}